RESEARCH PAPER
Medical marijuana – knowledge and opinions of primary care physicians in Lublin province, Poland
More details
Hide details
1
Department of Medical Anthropology, Institute of Rural Medicine, Lublin, Poland
2
Institute of Sociology, Maria Curie-Skłodowska University, Lublin, Poland
3
Department of Public Health, Medical Academy of Applied and Holistic Sciences, Warsaw, Poland
4
Department of Occupational Medicine, Medical University, Lublin, Poland
Corresponding author
Magdalena Florek-Łuszczki
Department of Medical Anthropology, Institute of Rural Medicine, Lublin, Jaczewskiego 2, 20-090, Lublin, Poland
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
After the legal approval of medical marijuana for therapeutic use in patients in Poland in 2017, it was important to assess the ability of primary care physicians (PCPs) to prescribe it to patients with various diseases. The aim of the study was to investigate the knowledge and opinions of PCPs regarding the possibility of prescribing medical marijuana, and in particular to obtain information about preparation of PCPs to prescribe it in clinical practice.
Material and methods:
A survey containing 28 questions was carried out from 2020 – 2022 among PCPs employed in primary healthcare in the Lublin province of Poland. Answers of 293 (out of 301) respondents underwent statistical analysis with CATREG (categorical regression with optimal scaling using alternating least squares) to determine predictors affecting the level of knowledge about medical marijuana.
Results:
Almost 90.8% of surveyed PCPs correctly identified the active ingredient of medical marijuana, assessed its acceptability (70.2%), differences in the use of marijuana and synthetic cannabinoids (60.1%), and the possibility of conducting clinical trials using cannabinoids in Poland (57.3%). Only 21.2% of respondents knew that there are legal guidelines in Poland, allowing the issue of prescriptions for medical marijuana, and 15.7% of respondents correctly identified the addictive potency of marijuana. The biggest problem for the surveyed PCPs was to indicate correct answers about the plants from which cannabinoids are extracted, the main physiological effects of marijuana and the negative consequences of its use.
Conclusions:
The surveyed PCPs self-esteemed that they have limited knowledge about medical marijuana and its clinical use in treating patients. More educational activities related with medical marijuana should be initiated for family doctors.
REFERENCES (34)
2.
Trevitt BT, Bailey S, Mills L, et al. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study. PloS One. 2024;19(2):e0297092.
https://doi.org/10.1371/journa....
7.
Peters EN, Yardley H, Harrison A, et al. A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). J Int Soc Sports Nutr. 2023;20(1):2280113.
https://doi.org/10.1080/155027....
12.
Belgers V, Röttgering JG, Douw L, et al. Cannabinoids to improve health-related quality of life in patients with neurological or oncological disease: a meta-analysis. Cannabis Cannabinoid Res. 2023;8(1):41–55.
https://doi.org/10.1089/can.20....
13.
Al-Khazaleh AK, Zhou X, Bhuyan DJ, et al. The neurotherapeutic arsenal in Cannabis sativa: insights into anti-neuroinflammatory and neuroprotective activity and potential entourage effects. Molecules. 2024;29(2):410.
https://doi.org/10.3390/molecu....
16.
Berg AT, Dixon-Salazar T, Meskis MA, et al. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey. Epilepsy Res. 2024;200:107280.
https://doi.org/10.1016/j.eple....
17.
Georgieva D, Langley J, Hartkopf K, et al. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. Epilepsy Behav. 2023;141:109159.
https://doi.org/10.1016/j.yebe....
26.
Abo Ziad R, Grynbaum MB, Peleg R, et al. The attitudes and beliefs of family physicians regarding the use of medical cannabis, knowledge of side effects, and barriers to use: a comparison between residents and specialists. Am J Therap. 2022;29(4):e400–e9.
https://doi.org/10.1097/MJT.00....
32.
Cheng KYC, Harnett JE, Davis SR, et al. Healthcare professionals’ perspectives on the use of medicinal cannabis to manage chronic pain: a systematic search and narrative review. Pain Pract. 2022;22(8):718–32.
https://doi.org/10.1111/papr.1....